Applikon Biotechnology acquires biotech portfolio from HaloteC Instruments

Bioreactor systems company Applikon Biotechnology has signed a definitive agreement to acquire the biotechnology portfolio of HaloteC Instruments, a Dutch provider of instruments and software solutions for the biotech market.

“Applikon Biotechnology is committed to continuing to deliver products and software innovations that bring significant efficiencies to our customers while simplifying operations in the biotech laboratories,” said Arthur Oudshoorn, CEO of Applikon Biotechnology. “We believe that the acquisition of the biotech portfolio of HaloteC Instruments will accelerate our development of bioreactor software solutions, allowing our customers to greatly improve the efficiency and performance of their R&D departments.”

As part of its strategy to deliver an advanced data centre for biotech processes, Applikon Biotechnology continues to invest and innovate to extend the benefits of instrumentation and software solutions for the bioprocess industry.

“Applikon Biotechnology and HaloteC Instruments share a highly aligned vision to remove complexity and increase efficiencies in the biotechnology-based R&D laboratories,” said Emo van Halsema, CEO of HaloteC. “We are excited to combine forces with Applikon to provide customers a more cost-effective, efficient and easy-to-operate solution for process development and optimisation.”

Applikon Biotechnology is represented in Australia and New Zealand by Enztech.